Protein Binding Drug Displacement Interactions Fact or Fiction?

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 1989 Feb 1

PMID 2656044

Citations 18

Authors

J J MacKichan

Affiliations

Soon will be listed here.

Citing Articles

Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis.

Hanafin P, Sermet-Gaudelus I, Griese M, Kappler M, Ellemunter H, Schwarz C Front Pharmacol. 2021; 12:577263.

PMID: 34408649 PMC: 8365608. DOI: 10.3389/fphar.2021.577263.

In vitro changes in the proportion of protein-unbound-free propofol induced by valproate.

Ishii-Maruhama M, Higuchi H, Nakanou M, Honda-Wakasugi Y, Yabuki-Kawase A, Maeda S J Anesth. 2018; 32(5):688-693.

PMID: 30062394 DOI: 10.1007/s00540-018-2540-6.

Contribution of baicalin on the plasma protein binding displacement and CYP3A activity inhibition to the pharmacokinetic changes of nifedipine in rats in vivo and in vitro.

Cheng Z, Tian X, Gao J, Li H, Jia L, Qiao H PLoS One. 2014; 9(1):e87234.

PMID: 24498050 PMC: 3907542. DOI: 10.1371/journal.pone.0087234.

The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery.

Smith D, Di L, Kerns E Nat Rev Drug Discov. 2010; 9(12):929-39.

PMID: 21119731 DOI: 10.1038/nrd3287.

Clinical pharmacokinetics and pharmacodynamics of repaglinide.

Hatorp V Clin Pharmacokinet. 2002; 41(7):471-83.

PMID: 12083976 DOI: 10.2165/00003088-200241070-00002.

References

Giacomini K, Swezey S, Giacomini J, Blaschke T . Administration of heparin causes in vitro release of non-esterified fatty acids in human plasma. Life Sci. 1980; 27(9):771-80. DOI: 10.1016/0024-3205(80)90331-8. View

Tsanaclis L, Allen J, Perucca E, Routledge P, Richens A . Effect of valproate on free plasma phenytoin concentrations. Br J Clin Pharmacol. 1984; 18(1):17-20. PMC: 1463568. DOI: 10.1111/j.1365-2125.1984.tb05015.x. View

Baciewicz A . Carbamazepine drug interactions. Ther Drug Monit. 1986; 8(3):305-17. DOI: 10.1097/00007691-198609000-00012. View

Liegler D, HENDERSON E, Hahn M, OLIVERIO V . The effect of organic acids on renal clearance of methotrexate in man. Clin Pharmacol Ther. 1969; 10(6):849-57. DOI: 10.1002/cpt1969106849. View

Knott C, Reynolds F . Phenytoin-valproate interaction: importance of saliva monitoring in epilepsy. Br Med J (Clin Res Ed). 1982; 284(6308):13-6. PMC: 1495384. DOI: 10.1136/bmj.284.6308.13. View

Leonard R, Knott P, Rankin G, Robinson D, Melnick D . Phenytoin-salicylate interaction. Clin Pharmacol Ther. 1981; 29(1):56-60. DOI: 10.1038/clpt.1981.10. View

Bjornsson T, Meffin P, Swezey S, Blaschke T . Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction. J Pharmacol Exp Ther. 1979; 210(3):316-21. View

Aarons L, Rowland M . Kinetics of drug displacement interactions. J Pharmacokinet Biopharm. 1981; 9(2):181-90. DOI: 10.1007/BF01068081. View

Perucca E, Hebdige S, Frigo G, Gatti G, Lecchini S, Crema A . Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects. Clin Pharmacol Ther. 1980; 28(6):779-89. DOI: 10.1038/clpt.1980.235. View

10.

Brown J, Kitchell B, Bjornsson T, SHAND D . The artifactual nature of heparin-induced drug protein-binding alterations. Clin Pharmacol Ther. 1981; 30(5):636-43. DOI: 10.1038/clpt.1981.215. View

11.

Yacobi A, Udall J, Levy G . Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect. Clin Pharmacol Ther. 1976; 19(5 Pt 1):552-8. DOI: 10.1002/cpt1976195part1552. View

12.

Sellers E, Lang M, Koch-Weser J, Colman R . Enhancement of warfarin-induced hypoprothrombinemia by triclofos. Clin Pharmacol Ther. 1972; 13(6):911-5. DOI: 10.1002/cpt1972136911. View

13.

Paxton J . Interaction of probenecid with the protein binding of methotrexate. Pharmacology. 1984; 28(2):86-9. DOI: 10.1159/000137947. View

14.

Wesseling H . Interaction of diphenylhydantoin (DPH) and tolbutamide in man. Eur J Clin Pharmacol. 1975; 8(1):75-8. DOI: 10.1007/BF00616418. View

15.

BOURKE R, Chheda G, Bremer A, Watanabe O, TOWER D . Inhibition of renal tubular transport of methotrexate by probenecid. Cancer Res. 1975; 35(1):110-6. View

16.

Fraser D, Ludden T, Evens R, Sutherland 3rd E . Displacement of phenytoin from plasma binding sites by salicylate. Clin Pharmacol Ther. 1980; 27(2):165-9. DOI: 10.1038/clpt.1980.25. View

17.

Oie S, Levy G . Effect of sulfisoxazole on pharmacokinetics of free and plasma protein-bound bilirubin in experimental unconjugated hyperbilirubinemia. J Pharm Sci. 1979; 68(1):6-9. DOI: 10.1002/jps.2600680106. View

18.

Paxton J . Effects of aspirin on salivary and serum phenytoin kinetics in healthy subjects. Clin Pharmacol Ther. 1980; 27(2):170-8. DOI: 10.1038/clpt.1980.26. View

19.

Kunin C . Clinical pharmacology of the new penicillins. II. Effect of drugs which interfere with binding to serum proteins. Clin Pharmacol Ther. 1966; 7(2):180-8. DOI: 10.1002/cpt196672180. View

20.

Chou R, Levy G . Effect of heparin or salicylate infusion on serum protein binding and on concentrations of phenytoin in serum, brain and cerebrospinal fluid of rats. J Pharmacol Exp Ther. 1981; 219(1):42-8. View